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Stem cells are immature, unspecialized cells that are able
to proliferate and population self-renewal. In tumor
mass, the cells with properties similar to stem cells are
present. These cells, so-called cancer stem cells (CSC),
are small subpopulation of cells, which can initiate the
tumor and cause the recurrence of the tumor. According
to published data, CSC have different level of sensitivity
to chemo- and radiotherapy, dependent, i. e. on its differ-
entiation state. It seems that complete recovery of the
patients is possible only when all CSC will be eliminated.
There are many of stem cell markers. In our research we
analyzed the expression of OCT4A splicing variant of
OCT4 (POU5F1) gene in preinvasive and malignant
lesions of the bladder. OCT4A is a marker of embrional
stem cells and, as transcription factor, is responsible for
sustaining the cells in undifferentiated state, characteris-
tic of the stem cell and potential to self-renewal. Our pre-
vious study suggested that its expression is observed in
premalignant and malignant lesions and are consistent
with results of other authors.
We examine archival, buffered formalin-fixed, paraf-
fin-embedded tissue samples of urinary bladder speci-
mens obtained from 113 patients. Expression of OCT4A
was detected using immunohistochemistry. The intensity
of OCT4A immunostaining was scored as 0 (negative), 1
(faint) or 2 (distinct) and OCT4A-positive cells were
analyzed as the numbers of cells per 1000 tumor cells.
Based on our results, we found the most intensive and
the most extensive (measured by means of percentage of
OCT4A-positive cells) expression of this marker in
urothelial cells at in situ stage. In papillary tumors (pTa)
and in situ cancers the percentage of OCT4A-positive
cells was higher when compared to less advanced inva-
sive cancers (pT1 and pT2), whereas the percentage of
OCT4A-positive cells in pTa tumors was similar to that
observed in invasive tumors at pT4 stage. The observed
differences were well-defined and statistically significant.
To summarize, the highest number and the most inten-
sive staining of OCT4A-positive cells in non-invasive
lesions pTis and pTa could suggest the important role of
OCT4A in initiation and promotion of invasive process.
It cannot be excluded that, analysis and evaluation of the
expression of this transcription factor can have predictive
value in the prediction of progression of pre-invasive
tumor to invasive form.
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